Defining ovarian reserve to better understand ovarian aging

<p>Abstract</p> <p>Though a widely utilized term and clinical concept, ovarian reserve (OR) has been only inadequately defined. Based on Medline and PubMed searches we here define OR in its various components, review genetic control of OR, with special emphasis on the <it>FMR...

Full description

Bibliographic Details
Main Authors: Gleicher Norbert, Weghofer Andrea, Barad David H
Format: Article
Language:English
Published: BMC 2011-02-01
Series:Reproductive Biology and Endocrinology
Online Access:http://www.rbej.com/content/9/1/23
id doaj-94a92029216b4f50a3b1f16ace8900a7
record_format Article
spelling doaj-94a92029216b4f50a3b1f16ace8900a72020-11-25T00:05:20ZengBMCReproductive Biology and Endocrinology1477-78272011-02-01912310.1186/1477-7827-9-23Defining ovarian reserve to better understand ovarian agingGleicher NorbertWeghofer AndreaBarad David H<p>Abstract</p> <p>Though a widely utilized term and clinical concept, ovarian reserve (OR) has been only inadequately defined. Based on Medline and PubMed searches we here define OR in its various components, review genetic control of OR, with special emphasis on the <it>FMR1 </it>gene, and discuss whether diminished OR (DOR) is treatable. What is generally referred to as OR reflects only a small portion of total OR (TOR), a pool of growing (recruited) follicles (GFs) at different stages of maturation. Functional OR (FOR) depends on size of the follicle pool at menarche and the follicle recruitment rate. Both vary between individuals and, at least partially, are under genetic control. The <it>FMR1 </it>gene plays a role in defining FOR at all ages. Infertility treatments have in the past almost exclusively only centered on the last two weeks of folliculogenesis, the gonadotropin-sensitive phase. Expansions of treatments into earlier stages of maturation will offer opportunity to significantly improve ovarian stimulation protocols, especially in women with DOR. Dehydroepiandrosterone (DHEA) may represent a first such intervention. Data generated in DHEA-supplemented women, indeed, suggest a new ovarian aging concept, based on aging of ovarian environments and not, as currently is believed, aging oocytes.</p> http://www.rbej.com/content/9/1/23
collection DOAJ
language English
format Article
sources DOAJ
author Gleicher Norbert
Weghofer Andrea
Barad David H
spellingShingle Gleicher Norbert
Weghofer Andrea
Barad David H
Defining ovarian reserve to better understand ovarian aging
Reproductive Biology and Endocrinology
author_facet Gleicher Norbert
Weghofer Andrea
Barad David H
author_sort Gleicher Norbert
title Defining ovarian reserve to better understand ovarian aging
title_short Defining ovarian reserve to better understand ovarian aging
title_full Defining ovarian reserve to better understand ovarian aging
title_fullStr Defining ovarian reserve to better understand ovarian aging
title_full_unstemmed Defining ovarian reserve to better understand ovarian aging
title_sort defining ovarian reserve to better understand ovarian aging
publisher BMC
series Reproductive Biology and Endocrinology
issn 1477-7827
publishDate 2011-02-01
description <p>Abstract</p> <p>Though a widely utilized term and clinical concept, ovarian reserve (OR) has been only inadequately defined. Based on Medline and PubMed searches we here define OR in its various components, review genetic control of OR, with special emphasis on the <it>FMR1 </it>gene, and discuss whether diminished OR (DOR) is treatable. What is generally referred to as OR reflects only a small portion of total OR (TOR), a pool of growing (recruited) follicles (GFs) at different stages of maturation. Functional OR (FOR) depends on size of the follicle pool at menarche and the follicle recruitment rate. Both vary between individuals and, at least partially, are under genetic control. The <it>FMR1 </it>gene plays a role in defining FOR at all ages. Infertility treatments have in the past almost exclusively only centered on the last two weeks of folliculogenesis, the gonadotropin-sensitive phase. Expansions of treatments into earlier stages of maturation will offer opportunity to significantly improve ovarian stimulation protocols, especially in women with DOR. Dehydroepiandrosterone (DHEA) may represent a first such intervention. Data generated in DHEA-supplemented women, indeed, suggest a new ovarian aging concept, based on aging of ovarian environments and not, as currently is believed, aging oocytes.</p>
url http://www.rbej.com/content/9/1/23
work_keys_str_mv AT gleichernorbert definingovarianreservetobetterunderstandovarianaging
AT weghoferandrea definingovarianreservetobetterunderstandovarianaging
AT baraddavidh definingovarianreservetobetterunderstandovarianaging
_version_ 1725425623125458944